Skip to main content
. 2020 Jun 17;8(1):e000612. doi: 10.1136/jitc-2020-000612

Figure 1.

Figure 1

PDS0101 monotherapy reduced tumor volume in the TC-1 syngeneic tumor model, and the combination of PDS0101, bintrafusp alfa and NHS-IL12 resulted in further tumor control. TC-1 tumor bearing female C57BL/6J mice (n=8–16 per group) were treated with PBS control (100 µL s.c), R-DOTAP control (100 µL s.c), PDS0101 (s.c., 3 weekly doses starting on day 7), bintrafusp alfa (250 µg, i.p., days 7, 9, and 11) and/or NHS-IL12 (50 µg, s.c., day 7). (A) Individual growth curves for PBS control, R-DOTAP, and PDS0101 treated mice. (B) Individual growth curves for PDS0101, bintrafusp alfa, and PDS0101 plus bintrafusp alfa treated mice. (C) Individual growth curves for PDS0101, NHS-IL12, and PDS0101 plus NHS-IL12 treated mice. (D) Individual growth curves for bintrafusp alfa, NHS-IL12, and bintrafusp alfa plus NHS-IL12 treated mice. (E) Individual growth curves for PDS0101, bintrafusp alfa, NHS-IL12, and PDS0101 plus bintrafusp alfa plus NHS-IL12 treated mice. (F) Tumor weights at the end of study. (G) Table of ‘tumor control’, the number of mice with tumors below 300 mm3 at the end of study. A meta-analysis of two independent experiments is shown. **P<0.01, ****P<0.0001. IL12, interleukin-12; i.p. intraperitoneally; s.c., subcutaneously.